Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stoke Therapeutics, Inc. (Nasdaq: STOK) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory disclosures. As a Nasdaq Global Select Market issuer, Stoke files current reports, annual reports, and other documents that describe its financial condition, governance, and progress in developing RNA-based medicines such as zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Current reports on Form 8-K document material events, including quarterly financial results, clinical and collaboration milestones, and changes in executive leadership. For example, Stoke has used Form 8-K to announce results of operations, disclose the appointment of its Chief Executive Officer and related employment and severance agreements, and furnish press releases about the initiation and progress of the global Phase 3 EMPEROR study of zorevunersen and the Phase 1 OSPREY study of STK-002.
Amended current reports on Form 8-K/A provide additional detail or updates on previously reported items, such as the company’s decisions regarding the frequency of advisory shareholder votes on executive compensation. These filings offer insight into Stoke’s corporate governance practices and board decisions.
Through Stock Titan, investors can also track periodic filings such as Forms 10-K and 10-Q when available, which typically include detailed discussions of Stoke’s TANGO antisense platform, its rare disease pipeline, collaboration agreements, and risk factors. Form 4 and related insider transaction filings, when present, can help users monitor equity awards and share transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand the significance of items such as clinical trial disclosures, collaboration terms, compensation arrangements, and shareholder voting outcomes. Real-time updates from the SEC’s EDGAR system ensure that new STOK filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are surfaced promptly for further review and analysis.
Morgan Stanley Smith Barney LLC lists proposed sales of Common shares in a Form 144 notice. The filing shows a proposed sale tied to an exercise of stock options dated 03/19/2026 for 1,365 shares and restricted stock units dated 12/01/2025 for 96 shares.
Stoke Therapeutics, Inc. filed a shelf registration and prospectus to offer $150,000,000 of common stock for sale from time to time under an at-the-market Controlled Equity Sales Agreement. The Sales Agreement with Cantor Fitzgerald & Co. permits offers from time to time after effectiveness.
The prospectus discloses that approximately 3.2 million shares have previously been sold for aggregate net proceeds of $87.8 million under an earlier prospectus supplement. The company states proceeds usage is general corporate purposes, including clinical development and manufacturing.
Stoke Therapeutics Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This was a derivative exercise (code M), not an open-market purchase or sale. Following the transaction, he directly owned 13,988 shares of common stock and 30,000 RSUs.
Each RSU converts into one share of common stock upon settlement. The RSU award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service. The reported ownership total also reflects 2,186 shares previously acquired through the company’s employee stock purchase plan.
Stoke Therapeutics Chief Financial Officer Thomas Leggett exercised restricted stock units into common shares in a routine compensation-related transaction. On March 15, 2026, he exercised 14,750 restricted stock units, receiving 14,750 shares of common stock at an exercise price of $0.00 per share.
After the transaction, Leggett directly holds 14,750 shares of common stock and 44,250 restricted stock units. Each RSU represents the right to receive one share of common stock upon settlement, and the award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service with the company.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares. On March 15, 2026, RSU awards covering 33,850 shares of common stock were settled at a price of $0.00 per share.
These RSU awards each represent the right to receive one share of common stock upon settlement and vest in annual 25% installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, subject to continued service. Following these transactions, Ticho directly holds 53,648 shares of Stoke Therapeutics common stock.
Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements. On March 15, 2026, he exercised or settled restricted stock units covering 61,750 shares of Common Stock at a stated price of $0.00 per share, reflecting equity compensation rather than open‑market purchases.
The RSU awards vest in annual installments of one quarter of the total shares beginning on March 15, 2024 and March 15, 2025, contingent on continued service. Following these transactions, Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Jonathan Allan, exercised restricted stock units and acquired common shares. On March 15, 2026, he exercised derivative awards covering 25,475 restricted stock units, each representing one share of common stock, at an exercise price of $0.00 per unit.
These exercises resulted in the acquisition of 25,475 shares of common stock, bringing his directly held common stock position to 37,731 shares following the transactions. Footnotes explain that each RSU converts into one share and that the RSU awards vest in annual installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, contingent on continued service.
Stoke Therapeutics director Arthur A. Levin reported an open-market sale of 605 shares of Common Stock at $36.80 per share on March 13, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.
After this sale, Levin directly holds 4,237 shares of Stoke Therapeutics common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, where he serves as trustee.
Stoke Therapeutics is a late-stage RNA medicines company using its proprietary TANGO antisense platform to upregulate protein expression for severe genetic diseases, especially autosomal dominant haploinsufficiencies of the central nervous system and eye.
The lead candidate, zorevunersen (STK-001), targets Dravet syndrome and is in the global Phase 3 EMPEROR trial, aiming to enroll about 150 patients, with pivotal data expected in mid‑2027 and a rolling NDA planned in 2027. Earlier Phase 1/2a and extension studies showed substantial, durable convulsive seizure reductions and improvements in cognition and behavior on top of standard anti‑seizure medicines, with zorevunersen generally well tolerated and holding FDA Breakthrough Therapy Designation.
The second clinical program, STK‑002 for autosomal dominant optic atrophy, is in the Phase 1 OSPREY trial after demonstrating preclinical proof‑of‑concept in restoring OPA1 protein and mitochondrial function. Stoke reports a broad TANGO-driven pipeline, a multijurisdictional patent estate extending into the 2030s–2040s, and major collaborations, including a $60 million upfront deal with Acadia around SYNGAP1 and a $165 million upfront global development and ex‑U.S. commercialization partnership with Biogen for zorevunersen.